Coloplast A/S (COLOb)

Copenhagen
Currency in DKK
629.8
-7.0(-1.10%)
Closed·
COLOb Scorecard
Full Analysis
Has raised its dividend for 16 consecutive years
Trading near 52-week Low
Fair Value
Day's Range
625.6641.0
52 wk Range
625.6959.0
Key Statistics
Edit
Prev. Close
636.8
Open
636
Day's Range
625.6-641
52 wk Range
625.6-959
Volume
290.72K
Average Volume (3m)
271.81K
1-Year Change
-25.4%
Book Value / Share
75.24
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
COLOb Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
751.9
Upside
+19.39%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period
Show more

Coloplast A/S Company Profile

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.

Employees
16741
Market
Denmark

Compare COLOb to Peers and Sector

Metrics to compare
COLOb
Peers
Sector
Relationship
P/E Ratio
31.2x29.8x−0.4x
PEG Ratio
−3.140.320.00
Price/Book
8.4x2.2x2.6x
Price / LTM Sales
5.1x2.7x2.9x
Upside (Analyst Target)
15.4%0.0%54.4%
Fair Value Upside
Unlock22.3%9.3%Unlock

Analyst Ratings

4 Buy
15 Hold
1 Sell
Ratings:
20 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 751.9
(+19.39% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 20.17%
Dividend Yield
3.49%
Industry Median 1.78%
Annualized payout
22.00
Paid unevenly
5-Years Growth
+5.29%
Growth Streak

Earnings

Latest Release
May 06, 2025
EPS / Forecast
4.34 / 5.39
Revenue / Forecast
6.93B / 7.01B
EPS Revisions
Last 90 days

People Also Watch

1,360.0
GMAB
-2.68%
1,185.5
PNDORA
-0.55%
5.5480
CPRI
-1.49%
279.7
INVEb
-1.20%
55.62
KNEBV
-1.21%

FAQ

What Is the Coloplast (COLOb) Stock Price Today?

The Coloplast stock price today is 629.80

What Stock Exchange Does Coloplast Trade On?

Coloplast is listed and trades on the Copenhagen Stock Exchange stock exchange.

What Is the Stock Symbol for Coloplast?

The stock symbol for Coloplast is "COLOb."

Does Coloplast Pay Dividends? What’s The Current Dividend Yield?

The Coloplast dividend yield is 3.49%.

What Is the Coloplast Market Cap?

As of today, Coloplast market cap is 141.81B.

What Is Coloplast's Earnings Per Share (TTM)?

The Coloplast EPS (TTM) is 20.17.

When Is the Next Coloplast Earnings Date?

Coloplast will release its next earnings report on Aug 19, 2025.

From a Technical Analysis Perspective, Is COLOb a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Coloplast Stock Split?

Coloplast has split 5 times.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.